NanoViricides Attempts to Leverage Decades of Combined Pharmaceutical and Biotech Experience To Bring Broad-Spectrum COVID-19 Antiviral to Market

Image provided by Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

The biotech industry has outperformed the S&P 500 for the last 2 years, growing by 62% compared to the S&P 500’s 47% growth in the same time period. The surge in investor interest might be largely driven by the pandemic, but the technology the influx of capital is funding will likely continue to impact the medical space long after the pandemic ends. 

With larger companies like Pfizer Inc. PFE and Moderna Inc. MRNA making headlines with a record $60 billion in combined sales of their COVID-19 vaccines — both vaccines based on mRNA technology that was so new it had never been cleared for human use before now — it’s no surprise investors are eager to find the next breakout biotech that will revolutionize medicine.

According to the Harvard Business Review, however, only about 10% to 20% of drug candidates beginning clinical trials ultimately gain approval for commercial sale, meaning investors need to be careful about which innovative ideas they put their money toward. Beating those odds takes more than just exciting ideas that drum up investor interest. It can take in-depth scientific expertise and the skill to translate those exciting ideas into safe and effective treatments. 

NanoViricides Inc. NNVC states that it boasts a strong team of scientific minds with decades of experience in the field that it believes will give it the edge needed to lead the nanomedicine market with its NanoViricide platform.

A Closer Look at NanoViricides’s Directors and Scientific Advisory Board

NanoViricides President and Chairman Anil R. Diwan, Ph.D.,  brings more than 25 years of research and development experience in the biopharmaceutical space as well as over 20 years of entrepreneurial experience. He’s been working on nanomedicine tech since 1991 and, in that time, has developed a large portfolio of small chemicals, devices, and informatics.

Randall W. Barton, Ph.D., is the company’s chief scientific officer. With a background in immunology and virology, Barton has more than 80 scientific publications to his name and 5 patents based on his research. He’s well versed in drug discovery and development, having spent 20 years as a director at Boehringer Ingelheim Pharmaceuticals conducting pre-clinical research before joining NanoViricides. 

The scientific advisory board also consists of researchers from Yale University’s School of Medicine, Memorial Sloan Kettering Cancer Center, and the University of Chicago. NanoViricides hopes that its team has the expertise and knowledge to achieve its goals.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.